Rabbit polyclonal antibody directed against human cytomegalovirus protein gL

Case ID:
Web Published:
Technology Overview: Rabbit polyclonal antisera against human cytomegalovirus (CMV) protein gL has been developed. This antisera is useful for research involving CMV. Please refer to the following publication for more information on this antisera.

Publication: Ryckman B.J., Rainish B.L., Chase M.C., Borton J.A., Nelson, J.A., Jarvis M.A., Johnson D.C. Characterization of the Human Cytomegalovirus gH/gL/UL128-131 complex that mediates entry into epithelial and endothelial cells. J. Virology (2008) 82(1):60-70.

Licensing Opportunity: The polyclonal antisera is available for non-exclusive licensing.

Aliquot provided: 0.5mL aliquots are provided. A minimum of three (3) aliquots of any combination of polyclonal antisera classified under OHSU Technology #1260 is required for each license/MTA.

Patent Information:
Biological Materials
For Information, Contact:
Trina Voss
Technology Development Manager
Oregon Health & Science University
David Johnson
Biological Materials
Biological Materials - Antibodies
Research Tools
Research Tools - Reagents
© 2023. All Rights Reserved. Powered by Inteum